Replicel Life Sciences Inc
XTSX:RP
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
0.01
0.1
|
Price Target |
|
We'll email you a reminder when the closing price reaches CAD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Net Margin
Replicel Life Sciences Inc
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
Country | CA |
Market Cap | 614.3k CAD |
Net Margin |
-20%
|
Country | US |
Market Cap | 1.3T USD |
Net Margin |
9%
|
Country | US |
Market Cap | 196.3B USD |
Net Margin |
14%
|
Country | US |
Market Cap | 170.3B USD |
Net Margin |
18%
|
Country | KR |
Market Cap | 66.5T KRW |
Net Margin |
24%
|
Country | CH |
Market Cap | 37.6B CHF |
Net Margin |
9%
|
Country | US |
Market Cap | 38.5B USD |
Net Margin |
22%
|
Country | US |
Market Cap | 36.7B USD |
Net Margin |
9%
|
Country | US |
Market Cap | 26.4B USD |
Net Margin |
21%
|
Country | US |
Market Cap | 23B USD |
Net Margin |
17%
|
Country | US |
Market Cap | 22.3B USD |
Net Margin |
-36%
|
Replicel Life Sciences Inc
Glance View
RepliCel Life Sciences, Inc. is a regenerative medicine company, which engages in the development of autologous cell therapies that treat functional cellular deficits including chronic tendon injuries, androgenetic alopeci, and skin aging. The company is headquartered in Vancouver, British Columbia and currently employs 1 full-time employees. The company went IPO on 2012-09-29. The company is focused on developing autologous cell therapies that treat functional cellular deficits including chronic tendon injuries, androgenetic alopecia, and skin aging. Its product pipeline includes RCT-01 for Tendon Repair, RCS-01 for Skin Rejuvenation, RCH-01 Hair Growth and RCI-02 Dermal Injector Publication . RCT-01 is an autologous cell-based treatment utilizing non-bulbar dermal sheath cells isolated from the hair follicle for the treatment of chronic Achilles tendinopathy. RCS-01 is an autologous cell therapy being developed to rejuvenate aging or Ultraviolet (UV)-damaged skin. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCI-02 is a dermal injector designed to deliver a variety of injectable substances in and under the skin with a range of needle configurations.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on Replicel Life Sciences Inc's most recent financial statements, the company has Net Margin of -19.6%.